Please use this identifier to cite or link to this item:
Type: Artigo
Title: Safety Of Switching From Natalizumab Straight Into Fingolimod In A Group Of Jcv-positive Patients With Multiple Sclerosis
Author: Fragoso
Yara Dadalti; Alves-Leon
Soniza Vieira; Becker
Jefferson; Bidin Brooks
Joseph Bruno; Correa
Eber Castro; Damasceno
Alfredo; da Gama
Paulo Diniz; da Gama
Rodrigo Assad; da Cunha Matta
Andre Palma; Maciel
Ernane Pires; d'Avila Winckler
Thereza Cristina
Abstract: To assess safety of the switch between natalizumab and fingolimod without a washout period. Methods: Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. Results: After a median period of nine months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events were reported. Conclusion: Washout may not be necessary in daily practice when switching from natalizumab to fingolimod. Expertise on multiple sclerosis management, however, is essential for drug switching.
Subject: Multiple Sclerosis
Fingolimod Hydrochloride
Editor: Assoc Arquivos Neuro- Psiquiatria
São Paulo
Rights: aberto
Identifier DOI: 10.1590/0004-282X20160090
Date Issue: 2016
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
000382419800010.pdf85.71 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.